Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] 900 Walnut Street,Jefferson Hospital for Neuroscience
[2] Second Floor,Montefiore Headache Center, Department of Neurology, Department of Epidemiology and Population Health
[3] Suite #200,Headache Center of Southern California
[4] University of South Alabama College of Medicine,undefined
[5] George Washington School of Medicine,undefined
[6] Allergan plc,undefined
[7] Albert Einstein College of Medicine,undefined
[8] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; onabotulinumtoxinA; Migraine; Allodynia; Disability; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [22] The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study
    Tepper, S.
    Wilson, M. -C.
    Orejudos, A.
    Adams, A. Manack
    Blumenfeld, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 78 - 78
  • [23] The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study
    Tepper, S. J.
    Wilson, M.
    Orejudos, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2018, 58 : 93 - 94
  • [24] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day: A COMPEL Subanalysis
    Lopez, Jorge Ivan
    Blumenfeld, Andrew M.
    Young, William B.
    Adams, Aubrey Manack
    Rothrock, John F.
    CEPHALALGIA, 2017, 37 : 99 - 100
  • [25] Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study
    Rothrock, John F.
    Luo, Lei
    Eross, Eric
    Sommer, Katherine
    Blumenfeld, Andrew M.
    NEUROLOGY, 2020, 94 (15)
  • [26] Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study
    Rothrock, J. F.
    Luo, L.
    Eross, E. J.
    Sommer, K.
    Blumenfeld, A. M.
    HEADACHE, 2020, 60 : 93 - 93
  • [27] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day: A COMPEL Subanalysis
    Lopez, J. Ivan
    Blumenfeld, Andrew M.
    Young, William B.
    Adams, Aubrey Manack
    Rothrock, John F.
    NEUROLOGY, 2018, 90
  • [28] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, P. K.
    Blumenfeld, A.
    Eross, E. J.
    Orejudos, A.
    Adams, Manack A.
    Brin, M. F.
    HEADACHE, 2018, 58 : 105 - 105
  • [29] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    CEPHALALGIA, 2017, 37 : 93 - +
  • [30] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Brin, Mitchell F.
    Winner, Paul
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    NEUROLOGY, 2018, 90
12345